Allergan announces worldwide recall of textured breast implant tied to rare cancer
The U.S. Food and Drug Administration said it called for the removal after new information showed Allergan Inc's Biocell breast implants account for a disproportionate share of rare lymphoma cases. The move follows similar bans by regulators in France, Australia and Canada.
Washington: Medical device maker Allergan Inc. is recalling a type of breast implant linked to a rare form of cancer.
The company Wednesday announced a worldwide recall of implants with a textured surface.
The U.S. Food and Drug Administration said it called for the removal after new information showed Allergan's Biocell breast implants account for a disproportionate share of rare lymphoma cases. The move follows similar bans by regulators in France, Australia and Canada.
Also Read: Abbvie finalizes deal to buy Botox maker Allergan for $63 billion
The FDA is not recommending women with the implants have them removed if they are not experiencing problems.
The recalled implants feature a textured surface designed to prevent slippage and to minimize scar tissue. Such models account for just 5% of the U.S. market. Most U.S. breast implants are smooth.
Also Read: Pfizer gets European nod for breast cancer treatment Talzenna
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd